Breakout Sessions : Oncology “First Launch” and Partnering

jun 5, 2019: 1:45 p.m. - 2:45 p.m.
105AB, Level 100

With multiple oncology "first launch" successes in recent years, most oncology emerging pharma company boards and executive teams will consider this increasingly attractive path to commercialization, often in parallel to partnering. Data shared during this panel, from all US oncology emerging pharma "first launches," will support discussion topics including: US, EU and RoW first launch benchmarks, preparing to launch vs exit or co-promote, special challenges in personalized medicine, rare oncology indications and "novel" technologies and innovation in "first launches" (customer experience, multi-channel commercial models and the role of analytics, AI and machine learning).


John Demaree
Chief Commercial officer

Mohamed Ladha
VP and Head of Commercial

Christopher Pierce
VP, Commercial

Ben Hohn

Alan Bash
Senior Vice President,...